Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is characterized by high recurrence, metastasis, and therapeutic resistance, with cancer stem cells (CSCs) contributing substantially to these malignant features. In this study, we identify WD repeat-containing protein 76 (WDR76) as a key oncofetal regulator of liver cancer stemness. Transcriptomic profiling of an in vitro hepatocyte differentiation model revealed that WDR76 is highly expressed in embryonic stem cells, suppressed during hepatocyte maturation, and aberrantly reactivated in HCC. Clinically, WDR76 upregulation correlated with poor differentiation, advanced stage, and reduced patient survival. Functional assays demonstrated that WDR76 enhances CSC-like properties, including self-renewal, invasion, and lenvatinib resistance, while suppressing hepatocytic differentiation. Mechanistically, WDR76 recruits the deubiquitinase USP14 to stabilize the chromatin-binding protein CBX5 by preventing its ubiquitination and degradation. Stabilized CBX5 undergoes liquid-liquid phase separation, promoting heterochromatin condensation and chromatin reprogramming, thereby activating stemness-associated genes. Loss-and gain-of-function studies confirmed CBX5 as an essential downstream effector of WDR76 in driving HCC stemness and tumor progression. Finally, siRNA-loaded nanoparticles targeting WDR76 synergized with lenvatinib to suppress tumor growth in preclinical models. Together, these findings establish a WDR76-USP14-CBX5 axis as a pivotal pathway sustaining CSC phenotypes and nominate WDR76 as a promising diagnostic and therapeutic target in HCC.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: